tradingkey.logo
๎™

Nuwellis Inc

NUWE
2.160USD
0.000
์ข…๊ฐ€ย 12/19, 16:00๏ผˆET๏ผ‰์‹œ์„ธ๋Š” 15๋ถ„ ์ง€์—ฐ๋ฉ๋‹ˆ๋‹ค
2.95M์‹œ๊ฐ€์ด์•ก
0.01P/E TTM
๎™

์ž์„ธํ•œ ๋‚ด์šฉ์€ Nuwellis Inc ํšŒ์‚ฌ

Nuwellis, Inc. is a commercial-stage medical technology company. The Company is focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems (collectively the Aquadex System). The Aquadex SmartFlow system is indicated for temporary or extended use in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics. The Aquadex System is designed to remove excess fluid from patients suffering from fluid overload who have failed diuretic therapy. The Aquadex System consists of a console, which is a piece of equipment containing electromechanical pumps and a liquid crystal display (LCD) screen; a one-time disposable blood circuit set, which is an integrated collection of tubing, filters, sensors, and connectors that contain and deliver the blood from and back to the patient, and a disposable catheter.

Nuwellis Inc ์ •๋ณด

๎™Œ
์ข…๋ชฉ ์ฝ”๋“œ NUWE
ํšŒ์‚ฌ ์ด๋ฆ„Nuwellis Inc
์ƒ์žฅ์ผFeb 16, 2012
CEOErb (John L)
์ง์› ์ˆ˜38
์œ ํ˜•Ordinary Share
ํšŒ๊ณ„ ์—ฐ๋„ ์ข…๋ฃŒFeb 16
์ฃผ์†Œ12988 Valley View Rd
๋„์‹œEDEN PRAIRIE
์ฆ๊ถŒ ๊ฑฐ๋ž˜์†ŒNASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐ€United States of America
์šฐํŽธ ๋ฒˆํ˜ธ55344
์ „ํ™”19523454200
์›น์‚ฌ์ดํŠธhttps://www.nuwellis.com/
์ข…๋ชฉ ์ฝ”๋“œ NUWE
์ƒ์žฅ์ผFeb 16, 2012
CEOErb (John L)

Nuwellis Inc์˜ ํšŒ์‚ฌ ์ž„์›์ง„

๎™Œ
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Erb (John L)
Erb (John L)
Chairman of the Board, President, Chief Executive Officer, Interim Chief Financial Officer, Interim Principal Financial Officer and Interim Principal Accounting Officer
Chairman of the Board, President, Chief Executive Officer, Interim Chief Financial Officer, Interim Principal Financial Officer and Interim Principal Accounting Officer
803.00
--
Dr. Archelle (Feldshon) Georgiou, M.D.
Dr. Archelle (Feldshon) Georgiou, M.D.
Independent Director
Independent Director
3.00
--
Mr. David Alan (Dave) Mcdonald
Mr. David Alan (Dave) Mcdonald
Independent Director
Independent Director
3.00
--
Mr. Gregory D. (Greg) Waller
Mr. Gregory D. (Greg) Waller
Independent Director
Independent Director
--
--
Mr. Neil P. Ayotte, Esq.
Mr. Neil P. Ayotte, Esq.
Senior Vice President, General Counsel, Secretary and Chief Compliance Officer
Senior Vice President, General Counsel, Secretary and Chief Compliance Officer
--
--
Dr. Maria Rosa Costanzo, M.D.
Dr. Maria Rosa Costanzo, M.D.
Independent Director
Independent Director
--
--
Mr. Michael (Mike) Mccormick
Mr. Michael (Mike) Mccormick
Lead Independent Director
Lead Independent Director
--
--
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Erb (John L)
Erb (John L)
Chairman of the Board, President, Chief Executive Officer, Interim Chief Financial Officer, Interim Principal Financial Officer and Interim Principal Accounting Officer
Chairman of the Board, President, Chief Executive Officer, Interim Chief Financial Officer, Interim Principal Financial Officer and Interim Principal Accounting Officer
803.00
--
Dr. Archelle (Feldshon) Georgiou, M.D.
Dr. Archelle (Feldshon) Georgiou, M.D.
Independent Director
Independent Director
3.00
--
Mr. David Alan (Dave) Mcdonald
Mr. David Alan (Dave) Mcdonald
Independent Director
Independent Director
3.00
--
Mr. Gregory D. (Greg) Waller
Mr. Gregory D. (Greg) Waller
Independent Director
Independent Director
--
--
Mr. Neil P. Ayotte, Esq.
Mr. Neil P. Ayotte, Esq.
Senior Vice President, General Counsel, Secretary and Chief Compliance Officer
Senior Vice President, General Counsel, Secretary and Chief Compliance Officer
--
--
Dr. Maria Rosa Costanzo, M.D.
Dr. Maria Rosa Costanzo, M.D.
Independent Director
Independent Director
--
--

์ˆ˜์ต ๋ถ„์„

๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.
๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.
์‚ฌ์—…๋ณ„
์ง€์—ญ๋ณ„
๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.

์ฃผ์‹ ๋ณด์œ  ํ†ต๊ณ„

๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Mon, Nov 17
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Mon, Nov 17
์ฃผ์ฃผ
์ฃผ์ฃผ ์œ ํ˜•
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น„์œจ
DRW Securities, LLC
2.18%
Sabby Management, LLC
2.16%
Bigger Capital Funds, LP
0.34%
UBS Financial Services, Inc.
0.17%
Citi Investment Research (US)
0.13%
๊ธฐํƒ€
95.02%
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น„์œจ
DRW Securities, LLC
2.18%
Sabby Management, LLC
2.16%
Bigger Capital Funds, LP
0.34%
UBS Financial Services, Inc.
0.17%
Citi Investment Research (US)
0.13%
๊ธฐํƒ€
95.02%
์ฃผ์ฃผ ์œ ํ˜•
์ฃผ์ฃผ
๋น„์œจ
Investment Advisor
2.35%
Investment Advisor/Hedge Fund
2.16%
Hedge Fund
0.41%
Research Firm
0.13%
Individual Investor
0.02%
๊ธฐํƒ€
94.93%

๊ธฐ๊ด€ ์ฃผ์‹ ๋ณด์œ 

๎™Œ
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Wed, Oct 1
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Wed, Oct 1
๋ณด๊ณ  ๊ธฐ๊ฐ„
๊ธฐ๊ด€ ์ˆ˜
๋ณด์œ  ์ฃผ์‹
๋น„์œจ
๋ณ€๋™
2025Q3
18
13.52K
2.03%
+10.09K
2025Q2
27
9.97K
1.46%
+7.11K
2025Q1
26
140.31K
3.15%
+23.64K
2024Q4
25
113.78K
2.60%
+73.44K
2024Q3
29
65.32K
2.68%
+45.76K
2024Q2
28
42.02K
3.15%
+30.15K
2024Q1
26
9.25K
4.91%
+1.97K
2023Q4
26
6.22K
6.75%
+3.61K
2023Q3
35
1.28K
4.82%
-1.76K
2023Q2
36
1.31K
5.00%
-797.00
๋” ๋ณด๊ธฐ

์ฃผ์ฃผ ํ™œ๋™

๎™Œ
์ด๋ฆ„
๋ณด์œ  ์ฃผ์‹
๋น„์œจ
๋ณ€๋™
Chg %
๋‚ ์งœ
Sabby Management, LLC
3.52K
0.67%
+3.52K
--
Jun 30, 2025
Bigger Capital Funds, LP
5.69K
0.63%
+5.69K
--
Jun 09, 2025
UBS Financial Services, Inc.
1.88K
0.36%
+1.78K
+1797.98%
Jun 30, 2025
Tower Research Capital LLC
132.00
0.01%
-14.00
-9.59%
Jun 30, 2025
Erb (John L)
803.00
0.02%
+803.00
--
Jun 10, 2025
SBI Securities Co., Ltd.
61.00
0.01%
+52.00
+577.78%
Jun 30, 2025
The Vanguard Group, Inc.
31.00
0%
--
--
Aug 31, 2025
BofA Global Research (US)
1.00
0%
--
--
Jun 30, 2025
๋” ๋ณด๊ธฐ

๊ด€๋ จ ETF

๎™Œ
์ด๋ฆ„
๋น„์œจ
๋ฐ์ดํ„ฐ ์—†์Œ

์ฃผ์‹ ๋ฐฐ๋‹น๊ธˆ

๎™Œ
์ง€๋‚œ 5๋…„ ๋™์•ˆ ์ด 0.00 USD์˜ ๋ฐฐ๋‹น๊ธˆ์ด ๋ถ„๋ฐฐ๋˜์—ˆ์Šต๋‹ˆ๋‹ค.
๋‚ ์งœ
๋ฐฐ๋‹น๊ธˆ
๊ธฐ์ค€์ผ
์ง€๊ธ‰์ผ
๋ฐฐ๋‹น๋ฝ์ผ
๋ฐ์ดํ„ฐ ์—†์Œ

์ฃผ์‹ ๋ถ„ํ• 

๎™Œ
๋‚ ์งœ
์œ ํ˜•
๋น„์œจ
Jul 02, 2025
Merger
42โ†’1
Jun 26, 2024
Merger
35โ†’1
Jun 26, 2024
Merger
35โ†’1
Jun 26, 2024
Merger
35โ†’1
Jun 26, 2024
Merger
35โ†’1
Dec 09, 2022
Merger
100โ†’1
๋‚ ์งœ
์œ ํ˜•
๋น„์œจ
Jul 02, 2025
Merger
42โ†’1
Jun 26, 2024
Merger
35โ†’1
Jun 26, 2024
Merger
35โ†’1
Jun 26, 2024
Merger
35โ†’1
Jun 26, 2024
Merger
35โ†’1
Dec 09, 2022
Merger
100โ†’1
Dec 09, 2022
Merger
100โ†’1
Dec 09, 2022
Merger
100โ†’1
Dec 09, 2022
Merger
100โ†’1
Oct 17, 2020
Merger
30โ†’1
๋” ๋ณด๊ธฐ

์ž์ฃผ ๋ฌป๋Š” ์งˆ๋ฌธ

Nuwellis Inc์˜ ์ƒ์œ„ 5๋Œ€ ์ฃผ์ฃผ๋Š” ๋ˆ„๊ตฌ์ธ๊ฐ€์š”?

๎™Œ
Nuwellis Inc์˜ ์ƒ์œ„ 5๋Œ€ ์ฃผ์ฃผ๋Š” ๋‹ค์Œ๊ณผ ๊ฐ™์Šต๋‹ˆ๋‹ค:
Sabby Management, LLC๋Š” 3.52K์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 0.67%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.
Bigger Capital Funds, LP๋Š” 5.69K์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 0.63%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.
UBS Financial Services, Inc.๋Š” 1.88K์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 0.36%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.
Tower Research Capital LLC๋Š” 132.00์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 0.01%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.
Erb (John L)๋Š” 803.00์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 0.02%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.

Nuwellis Inc์˜ ์ƒ์œ„ 3๋Œ€ ์ฃผ์ฃผ ์œ ํ˜•์€ ๋ฌด์—‡์ธ๊ฐ€์š”?

๎™Œ
Nuwellis Inc์˜ ์ฃผ์š” ์ฃผ์ฃผ ์œ ํ˜• ์ƒ์œ„ 3๊ฐ€์ง€๋Š”
DRW Securities, LLC
Sabby Management, LLC
Bigger Capital Funds, LP์ž…๋‹ˆ๋‹ค.

Nuwellis Inc(NUWE)์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•œ ๊ธฐ๊ด€์€ ๋ช‡ ๊ฐœ์ž…๋‹ˆ๊นŒ?

๎™Œ
2025Q3 ๊ธฐ์ค€์œผ๋กœ, Nuwellis Inc์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•œ ๊ธฐ๊ด€์€ ์ด 18๊ณณ์ด๋ฉฐ, ์ด๋“ค์ด ๋ณด์œ ํ•œ ์ฃผ์‹์˜ ์ด ๊ฐ€์น˜๋Š” ์•ฝ 13.52K๋กœ ์ „์ฒด ๋ฐœํ–‰ ์ฃผ์‹์˜ 2.03%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค. ์ด๋Š” 2025Q2 ๋Œ€๋น„ 0.57% ์ฆ๊ฐ€ํ•œ ์ˆ˜์น˜์ž…๋‹ˆ๋‹ค.

Nuwellis Inc์˜ ์ตœ๋Œ€ ์ˆ˜์ต์›์€ ๋ฌด์—‡์ธ๊ฐ€์š”?

๎™Œ
-- ๊ธฐ์ค€, Nuwellis Inc์˜ -- ๋ถ€๋ฌธ์ด ๊ฐ€์žฅ ๋†’์€ ๋งค์ถœ์„ ๊ธฐ๋กํ–ˆ์œผ๋ฉฐ, ๊ธˆ์•ก์€ --๋กœ ์ „์ฒด ๋งค์ถœ์˜ --%๋ฅผ ์ฐจ์ง€ํ–ˆ์Šต๋‹ˆ๋‹ค.
KeyAI
๎™